Oncimmune Holdings PLC's (LON:ONC) Adam Hill tells Proactive London about their master service agreement with California-based immunotherapy specialist Augmenta Bioworks.
This collaboration will profile patient plasma samples and assess treatment candidates discovered using the latter’s SingleCyte and DeepGrid platforms.
Hill says the first project will be used to identify potential therapeutic antibodies that bind to human antigens found in cancer patients.
